Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multi-cohort, Multi-center Phase II Basket Clinical Study of RC48-ADC Monotherapy in the Treatment of HER2-expressing (HER2-positive and HER2 Low Expression) Gynecological Malignancies

Next Previous
X
Search
Trial Profile

An Open, Multi-cohort, Multi-center Phase II Basket Clinical Study of RC48-ADC Monotherapy in the Treatment of HER2-expressing (HER2-positive and HER2 Low Expression) Gynecological Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary)
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Squamous cell cancer; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Focus Therapeutic Use
  • Sponsors RemeGen

    • Most Recent Events

    • 04 Jun 2024 Interim Results (As of Oct 31, 2023, n=25) assessing safety and efficacy of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 10 Mar 2024 According to a RemeGen Co Media Release, as of October 31, 2023, 25 patients with cervical cancer were enrolled.
    • 10 Mar 2024 According to a RemeGen Co Media Release, data from this trial presented at the European Congress on Gynaecological Oncology (ESGO 2024 Congress).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top